Key facts
- J&J's Erleada combined with hormone therapy reduced the risk of prostate cancer spreading or death by 20% in a late-stage trial.
- The combination therapy resulted in nine times higher likelihood of little to no detectable cancer post-surgery compared to hormone therapy alone.
- A full year of combination therapy reduced the risk of recurrence and death by 29%.
- The study enrolled over 2,000 patients with high-risk localized or locally advanced prostate cancer.
- The safety profile of the Erleada combination treatment was consistent with previous studies.
The study results for J&J's Erleada are significant because they suggest a new treatment paradigm for high-risk localized or locally advanced prostate cancer. Current standard treatments include surgery and radiation therapy, but nearly half of patients see their cancer return. The data presented at the American Society of Clinical Oncology meeting indicates that Erleada, in combination with hormone therapy, could offer a more effective approach, potentially delaying or preventing the need for subsequent treatments.